Introduction

Osteoporosis is an important health problem and a major predisposing factor for fracture. As the population aging, the prevalence of osteoporosis gets higher and the social burden increasing. So it has been an important subject to investigate the factors that influence the occurrence of osteoporosis. Some of them were modifiable factors such as smoking, alcohol consumption, low calcium intake and others were not modifiable factors such as aging, female gender, menopause [1-3].

Recently, oxidative stress or low circulating levels of antioxidants were proposed to be related with reduced bone mineral density (BMD) and caused osteoporosis by in vitro studies or animal studies [4-6]. Uric acid, bilirubin and albumin has been known as natural antioxidants. Actually, it has been reported that higher
uric acid levels were linearly associated with higher lumbar spine BMD in perimenopausal and postmenopausal women. It might be due to the major role of uric acid in free radical scavenger activity [7]. Bilirubin suppressed oxidation and albumin was an important contributor to maintain total antioxidant status [8,9]. So, the antioxidant activity by these factors could be influence the BMD. On the contrary, homocysteine was a factor associated with oxidative stress in vivo [8,10]. But, the relationship between homocysteine and BMD is still unclear. Some studies reported that high homocysteine was related with increased bone turnover and fracture risk in elderly [11,12], but other studies didn’t [13,14]. Homocysteine level might be changed with endogenous sex steroids levels [15]. So, the change of homocysteine levels through the menopausal transition may have influence on the decrease of BMD or development of osteoporosis in postmenopausal women. The research for the relationship of natural antioxidants and BMD could confirm the influence of oxidative stress for development of osteoporosis and the natural antioxidants levels could be used as variables predicting the occurrence of osteoporosis. The aim of this study is to investigate the association between oxidative stress and BMD according to menopausal status of Korean women.

Materials and methods

1. Study population and anthropometric measurements
A total of 2,232 women who visited to the health promotion center at Pusan National University Hospital between 2010 and 2014 were included in this cross-sectional study. Demographic data were collected at the time of the visit. Information on menstrual history, lifestyle, disease history and medication history were obtained with self-report questionnaires and interviews with healthcare providers. Body weight and height were measured when standing barefoot, up to 0.1 kg and 0.1 cm, respectively. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.

We conducted our research based on self-report questionnaires. We included patients prepared our self-report questionnaires without exception and excluded patients who had been taking a steroid medicine for asthma, arthritis, rheumatic disease, which could affect BMD and also excluded patients taking a bisphosphonate and selective estrogen-receptor modulator. But we included 390 hypertension patients, 95 diabetes patients, 353 hyperlipidemia patient, all these patients had been taking a medication, 115 smokers. We also included patients had been taking a vitamin D or calcium medication on our research.

2. Blood sampling and laboratory analysis
Bloods were obtained from antecubital vein from all subjects between 8:30 and 10:00 a.m., after fasting for at least eight hours. Laboratory tests were evaluated, which consisted of uric acid, albumin, total bilirubin as a natural antioxidants and homocysteine as a factor associated with oxidative stress. BMD was measured by dual-energy X-ray absorptiometry (Hologic QDR-4500A, Bedford, MA, USA) at the lumbar spine (L1–L4), femur neck and femur total. BMD results were classified into three groups according to World Health Organization criteria (normal BMD, T-score ≥-1; osteopenia, -2.5< T-score <-1; and osteoporosis, T-score ≤-2.5, respectively) [16]. Intraassay and interassay coefficients of variation of uric acid were 1.0% and 1.3%, albumin were 1.6% and 0.9%, total bilirubin were 2.7% and 2.6%, homocysteine were 4.4% and 3.3%, BMD were 2.3% and 2.7%.

3. Statistical analysis
PASW ver. 18.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. All data were entered into a database and were

Table 1. Demographics and laboratory parameters of study population

| Parameters       | Premenopause (n=840) | Postmenopause (n=1,392) | P-valuea |
|------------------|----------------------|-------------------------|----------|
| Age (yr)         | 43.9±7.1             | 58.6±6.9                | 0.000    |
| Body mass index (kg/m²) | 21.9±2.9             | 23.1±3.0                | 0.000    |
| Total bilirubin (mg/dL) | 0.9±0.4              | 0.9±0.4                 | 0.267    |
| Albumin (g/dL)   | 4.4±0.9              | 4.4±0.3                 | 0.058    |
| Uric acid (mg/dL) | 4.3±0.9              | 4.6±1.1                 | 0.000    |
| Homocysteine (umol/L) | 7.2±5.9              | 7.6±2.9                 | 0.096    |

Data are presented as the mean±standard deviation.
aStudent’s t-test.
verified by a second independent person.

Data were presented as mean±standard deviation for normally distributed variables (age, BMI, albumin, total bilirubin, homocysteine, and uric acid). The study population was divided into two groups, premenopause and postmenopause. Menopause group was categorized according to self questionnaires. If the patient had a hysterectomy, menopause was diagnosed by serum follicle stimulating hormone level. Serum follicle stimulating hormone more than 40 IU/mL was used for diagnosis of menopause.

The differences in baseline characteristics between groups were analyzed by Student’s t-test. Correlation analyses and partial correlation coefficients were performed with Pearson test. Logistic regression analysis was performed to identify significant independent related factors for osteoporosis. Two-sided values of P<0.05 were considered as statistically significant.

Results

The demographics and laboratory parameters of the study participants were presented in Table 1. There were statistically significant differences on age, BMI, uric acid level between two groups (P< 0.05).

The correlation analysis results between oxidative stress markers with BMD scores according to menopausal status were summarized in Tables 2 and 3. Uric acid was a sole parameter that had significantly positive correlation with femur and lumbar BMD in premenopausal group with strongly, but the magnitude of correlation was small (r=0.143, P=0.000). In postmenopausal group, uric acid was positively correlated with lumbar BMD (r=0.095, P=0.000). Homocysteine had negative correlation significantly with femur BMD (r=-0.074, P=0.038). A positive correlation was found between total bilirubin level and femur BMD scores (r=0.069, P=0.010). But there were different results in partial correlation coefficient adjusted by age and BMI. In premenopausal group, uric acid was still positive correlation with femur and lumbar BMD, whereas in postmenopausal group homocysteine had no correlation with femur BMD (r=-0.032, P=0.372), total bilirubin and uric acid had no correlation with lumbar BMD.

Table 4 showed the results of multiple logistic regression analyses. BMD was calculated as continuous variable parameters and we investigated correlation of serial BMD score and several factors (uric acid, homocysteine, albumin, and total bilirubin). Cumulative logistic regression analyses revealed that age (odds ratio [OR], 0.934; 95% confidence interval [CI], 0.914 to 0.954; P<0.000), menopause (OR, 0.323; 95% CI, 0.214 to 0.491; P<0.000) and uric acid (OR, 1.208; 95% CI, 1.100 to 1.302;

Table 2. Correlation coefficients between bone mineral density scores and laboratory parameters associated with oxidative stress in premenopausal women

|                      | Femur bone mineral density | Lumbar bone mineral density |
|----------------------|----------------------------|-----------------------------|
|                      | Uric acid  | Homocysteine | Albumin  | Total bilirubin | Uric acid  | Homocysteine | Albumin  | Total bilirubin |
| r<sup>a</sup>        | 0.162      | -0.046       | -0.057   | -0.021          | 0.143      | -0.040       | -0.057   | -0.003          |
| P-value              | 0.000      | 0.305        | 0.096    | 0.538           | 0.000      | 0.372        | 0.096    | 0.963           |
| r<sup>b</sup>        | 0.127      | -0.036       | -0.003   | -0.013          | 0.092      | -0.032       | 0.050    | 0.026           |
| P-value              | 0.005      | 0.421        | 0.954    | 0.766           | 0.042      | 0.478        | 0.273    | 0.561           |

<sup>a</sup>Pearson’s correlation coefficient; <sup>b</sup>Partial correlation coefficient adjusted by age and body mass index.

Table 3. Correlation coefficients between bone mineral density scores and laboratory parameters associated with oxidative stress in postmenopausal women

|                      | Femur bone mineral density | Lumbar bone mineral density |
|----------------------|----------------------------|-----------------------------|
|                      | Uric acid  | Homocysteine | Albumin  | Total bilirubin | Uric acid  | Homocysteine | Albumin  | Total bilirubin |
| r<sup>a</sup>        | 0.052      | -0.074       | 0.048    | 0.069           | 0.095      | -0.042       | 0.020    | 0.037           |
| P-value              | 0.051      | 0.038        | 0.072    | 0.010           | 0.000      | 0.242        | 0.449    | 0.192           |
| r<sup>b</sup>        | -0.003     | -0.032       | 0.010    | 0.036           | 0.069      | -0.015       | -0.014   | 0.010           |
| P-value              | 0.931      | 0.372        | 0.786    | 0.313           | 0.056      | 0.685        | 0.763    | 0.786           |

<sup>a</sup>Pearson’s correlation coefficient; <sup>b</sup>Partial correlation coefficient adjusted by age and body mass index.
Table 4. Cumulative logistic regression analysis results of the possible correlates for lumbar (L1–L4) and femur bone mineral density

|                        |                           | 95% confidence interval | P-value$^b$ |
|------------------------|---------------------------|-------------------------|------------|
|                        | Odds ratio | Lower  | Upper  |            |            |
| Lumbar bone mineral density |            |        |        |            |            |
| Age                    | 0.934       | 0.914  | 0.954  | 0.000      |            |
| Menopause              | 1.676       | 1.509  | 1.786  | 0.000      |            |
| Uric acid              | 1.208       | 1.100  | 1.302  | 0.000      |            |
| Homocysteine           | 0.992       | 0.954  | 1.028  | 0.660      |            |
| Albumin                | 1.046       | 0.440  | 1.417  | 0.851      |            |
| Total albumin          | 1.017       | 0.617  | 1.302  | 0.920      |            |
| Femur bone mineral density |            |        |        |            |            |
| Age                    | 0.939       | 0.920  | 0.958  | 0.000      |            |
| Menopause              | 1.394       | 1.115  | 1.585  | 0.010      |            |
| Uric acid              | 1.165       | 1.054  | 1.263  | 0.005      |            |
| Homocysteine           | 0.991       | 0.960  | 1.021  | 0.550      |            |
| Albumin                | 0.670       | 0.463  | 1.174  | 0.238      |            |
| Total albumin          | 0.817       | 0.364  | 1.145  | 0.309      |            |

$^b$P<0.000) were independent variables associated with increasing lumbar and femur BMD.

Discussion

Oxidative stress has been proposed as an underlying mechanism of many diseases such as cancer, atherosclerosis, rheumatoid arthritis and osteoporosis [17]. Oxidative stress may cause osteoporosis by altering the function of osteoclast and osteoblast. Architecture of bone is maintained by continuous destruction and renewal of bone. These continuous remodeling of bone are regulated by balanced action of osteoclast and osteoblast. In osteoporosis patients, the ratio of superoxide dismutase and glutathione peroxidase, which were oxidative stress biological markers, were increased and it favors the increase in $\text{H}_2\text{O}_2$ levels [18,19]. High $\text{H}_2\text{O}_2$ levels developed the differentiation of osteoblastic cells to osteoclasts and inhibit the differentiation of osteoblastic cells to osteoblasts [20,21].

In addition, there were some reports that explained the effect of antioxidants to the development of osteoporosis. Low serum albumin reflected significant systemic inflammation and bone resorption had been found to be increased by systemic inflammation as a result of increased number of various cytokines [22]. There have been several epidemiological analyses that had shown a significant inverse association between total bilirubin and BMD in patients with or without underlying liver disease [23-25]. Low intake of antioxidant vitamins increased the risk of hip fracture in smoker [26]. Maggio et al. [27] also showed possible link between plasma antioxidants and BMD in osteoporotic women.

Despite of this clear causal relationship between oxidative stress and osteoporosis, factors that affect natural antioxidant have not been well identified. One of suggested factors is homocysteine. Homocysteine caused the production of reactive oxygen species by autooxidation [28]. Theoretically, homocysteine has negative effect on antioxidant and bone. But conflicting results have been reported about the relationship of homocysteine and bone.

Bucciarelli et al. [29] reported that total plasma homocysteine was negatively associated with the variance of BMD of the total femur. The association was clinically relevant but the contribution of homocysteine to BMD was small (2% of the total variance). On the contrary, Dhonukshe-Rutten et al. [30] and Fleming et al. [31] showed no relation between homocysteine and BMD. The transition of homocysteine level after menopause is also unclear. It has been reported that homocysteine was lower in premenopausal as compared to postmenopausal women [32]. However other researchers reported that menopause did not affect the homocysteine levels [33-35].

In this study, the average level of homocysteine was higher in the postmenopausal women but there was no statistical differ-
ence between premenopausal and postmenopausal women. On BMD, homocysteine had weakly negative correlation only in femur and no relationship with osteopenia or osteoporosis (data was not shown) and no correlation with BMD on cumulative logistic regression analysis. Albumin and total bilirubin were also showed weak or no relationship with BMD. Therefore, homocysteine, albumin and total bilirubin seemed not to be good parameters to predict the BMD in Korean women. Also, by the study of Kim et al. [36], serum homocysteine levels were not correlated with BMD in middle aged Korean women and it showed similar results of this study. Considering these results, homocysteine may have little significance on the correlation or prediction of BMD in Korean women. Actually homocysteine is influenced by many factors like age, race, alcohol intake, smoking, renal function and nutritional state [37-39]. Therefore, it may need homocysteine measurements under serial and more subdivided situation to confirm the relationship of homocysteine and BMD.

In point of the correlation of BMD and oxidative-antioxidative factors, Uric acid showed correlation with femur and lumbar BMD in premenopause and only lumbar BMD in postmenopause. Because the normal discordance of lumbar and femur BMD after menopause by increasing body fat mass was one of the reason for changes of statistical relationship of uric acid and BMD between premenopause and postmenopause women [40]. But uric acid and femur BMD in postmenopause showed tendency to positive correlation in our study (P=0.051). But there were different results in partial correlation coefficient adjusted by age and BMI. In premenopausal group, uric acid was still positive correlation with femur and lumbar BMD but it had no correlation with lumbar BMD in postmenopausal group. At cumulative logistic regression analyses, age, menopause state and uric acid were the independent factors that affect the lumbar and femur BMD. Ishii et al. [41] reported similar result. From these results, we can assume that uric acid is the leading natural anti-oxidant affecting BMD and might be used as a marker to represent natural antioxidative state.

This study was conducted to the women who visited health promotion center to check-up voluntary. The composition of object group in this study might give influence to the result. Also, there were plenty of oxidative and antioxidative parameters in vivo and the relation of these factors were much more complicated. Nevertheless these limitations, this study has values to show the relationship of natural antioxidant and BMD, and the changes of natural antioxidant depending on the menopausal status. This study examined limited kinds of natural antioxidant. Research for other natural antioxidants will be clearly revealed the association of BMD and oxidative stress and further investigation will be needed.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by grant no. 03-2006-0250 from Seoul National University Hospital Research Fund.

References

1. Eisman J, Clapham S, Kehoe L; Australian BoneCare Study. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 2004;19:1969-75.
2. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
3. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002;13:527-36.
4. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 2004;314:197-207.
5. Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 2004;314:197-207.
6. Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology
7. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858-62.

8. Reid IR, Ames RW, Evans MC, Sharpe SJ, Gamble GD. Determinants of the rate of bone loss in normal postmenopausal women. J Clin Endocrinol Metab 1994;79:950-4.

9. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998;44:1309-15.

10. Yavuz BB, Yavuz B, Halil M, Cankurtaran M, Ulger Z, Cankurtaran ES, et al. Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer’s disease. Int Psychogeriatr 2008;20:815-23.

11. Leboff MS, Narweker R, LaCroix A, Wu L, Jackson R, Lee J, et al. Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 2009;94:1207-13.

12. Van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.

13. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004;35:760-5.

14. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005;37:234-42.

15. Mijatovic V, van der Mooren MF. Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Clin Chem Lab Med 2001;39:764-7.

16. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999;10:259-64.

17. Kuyumcu ME, Yesil Y, Ozturk ZA, Cinar E, Kizilsarlanoglu C, Halil M, et al. The association between homocysteine (hcy) and serum natural antioxidants in elderly bone mineral densitometry (BMD). Arch Gerontol Geriatr 2012;55:739-43.

18. De Haan JB, Cristiano F, Iannello R, Bladier C, Kelner MJ, Kola I. Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum Mol Genet 1996;5:283-92.

19. Koningsberger JC, van Asbeck BS, van Faassen E, Wiegman LJ, van Hattum J, van Berge Henegouwen GP, et al. Copper, zinc-superoxide dismutase and hydrogen peroxide: a hydroxyl radical generating system. Clin Chim Acta 1994;230:51-61.

20. Sontakke AN, Tare RS. A duality in the roles of reactive oxygen species with respect to bone metabolism. Clin Chim Acta 2002;318:145-8.

21. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001;31:509-19.

22. Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 2010;69:1415-9.

23. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001;35:316-23.

24. Ormarsdottir S, Ljunggren O, Mallmin H, Michaelsson K, Loof L. Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2002;14:43-8.

25. Bian LQ, Li RZ, Zhang ZY, Jin YJ, Kang HW, Fang ZZ, et al. Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. J Bone Miner Res 2013;31:637-43.

26. Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S. Smoking, antioxidant vitamins, and the risk of hip fracture. J Bone Miner Res 1999;14:129-35.

27. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, et al. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 2003;88:1523-7.

28. Tyagi N, Kandel M, Munjal C, Qipshidze N, Vacek JC, Pushpakumar SB, et al. Homocysteine mediated decrease in bone blood flow and remodeling: role of folic acid. J Orthop Res 2011;29:1511-6.

29. Bucciarelli P, Martini G, Martinelli I, Ceccarelli E, Gennari L, Bader R, et al. The relationship between plasma homocysteine levels and bone mineral density in postmenopausal women. Eur J Intern Med 2010;21:301-5.
30. Dhonukshe-Rutten RA, Lips M, de Jong N, Chin A Paw MJ, Hiddink GJ, van Dusseldorp M, et al. Vitamin B-12 status is associated with bone mineral content and bone mineral density in frail elderly women but not in men. J Nutr 2003;133:801-7.

31. Fleming JT, Barati MT, Beck DJ, Dodds JC, Malkani AL, Parameswaran D, et al. Bone blood flow and vascular reactivity. Cells Tissues Organs 2001;169:279-84.

32. Hak AE, Polderman KH, Westendorp IC, Jakobs C, Hofman A, Witteman JC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000;149:163-8.

33. Christodoulakos G, Panoulis C, Rizos D, Moustakarias T, Phocas I, Creatsas G. Homocysteine and folate levels in postmenopausal women. Maturitas 2001;39:161-7.

34. Wouters MG, Moorrees MT, van der Mooren MJ, Blom HJ, Boers GH, Schellekens LA, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-5.

35. Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87.

36. Kim A, Lee JH, Lee JY, Oh YM, Hong SN, Choi H, et al. Association between serum homocysteine concentrations and bone mineral density in middle aged women. J Korean Soc Menopause 2013;19:81-6.

37. Rasmussen K, Møller J. Total homocysteine measurement in clinical practice. Ann Clin Biochem 2000;37:627-48.

38. Carmel R, Green R, Jacobsen DW, Rasmussen K, Florea M, Azen C. Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr 1999;70:904-10.

39. Cravo ML, Gloria LM, Selhub J, Nadeau MR, Camilo ME, Resende MP, et al. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 1996;63:220-4.

40. Kapus O, Gaba A, Svoboda Z, Botek M. Relationship between body composition and bone mineral density of the lumbar spine and proximal femur: influence of years since menopause. Mod Rheumatol 2014;24:505-10.

41. Ishii S, Miyao M, Mizuno Y, Tanaka-Ishikawa M, Akishita M, Ouchi Y. Association between serum uric acid and lumbar spine bone mineral density in peri- and postmenopausal Japanese women. Osteoporos Int 2014;25:1099-105.